pharma · Crohn's Disease · Ulcerative Colitis (UC)
AbbVie
AbbVie is a pharma organization headquartered in Hamilton, CN. Primary therapeutic focus areas include Crohn's Disease, Ulcerative Colitis (UC), Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa. NovaPh
Company details
- Status
- Public
- HQ
- 1 Waukegan Road, North Chicago, Illinois 60064, US
- Employees
- 60,084
- Programs
- 41
- Drugs
- 32
- Patents
- 25
Quick answer
AbbVie is a pharma organization headquartered in Hamilton, CN. Primary therapeutic focus areas include Crohn's Disease, Ulcerative Colitis (UC), Psoriatic Arthritis, Rheumatoid Arthritis, Hidradenitis Suppurativa. NovaPharmaNews links 41 clinical program(s), 14 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (32), phase 2 (5), phase 1 (2).
Company snapshot
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community g
- 12 approved product(s) across US/EU regulatory metadata.
- 41 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for AbbVie. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis
- approval
UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape
- approval
AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer
- trial_data
UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
- approval
AbbVie Secures FDA Approval for ImmunoGen's Elahere
- approval
AbbVie Plans Layoffs: Implications for the Pharma Industry
- approval
AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
- approval
AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
Recent coverage
AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.
AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.
AbbVie Secures FDA Approval for ImmunoGen's Elahere
Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere
AbbVie Plans Layoffs: Implications for the Pharma Industry
Structured plan for AbbVie Plans Layoffs: Implications for the Pharma Industry
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for AbbVie.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for AbbVie.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is AbbVie?
-
Is AbbVie publicly traded?
-
What drugs does AbbVie develop or market?
-
What are the latest developments for AbbVie?
-
What therapeutic areas does AbbVie focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.